Innovation

For 25 years, Johnson & Johnson has pursued innovative blood cancer treatments. Scientist Kodandaram “Ram” Pillarisetti has helped shape that pursuit, from discovering a target that led to an approved bispecific therapy to research exploring a next-generation trispecific antibody approach.

From suturing to robotics system training, the Johnson & Johnson Institute is bringing surgical education to busy HCPs so they can deliver safe, effective care.

Johnson & Johnson launched this competition with one goal: to accelerate the development of next-generation surgical technologies. Meet this year’s three awardees and learn about their innovations.

Learn about one employee’s very personal mission to help restore vision for people who undergo cataract surgery.

A Johnson & Johnson scientist explains how the Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye’s natural tear film and helps eyes easily switch focus from distance to reading.

Once considered a straightforward procedure to restore cloudy vision, cataract surgery has evolved into one of the most technologically advanced—and personalized—operations in modern medicine. Learn how Johnson & Johnson’s 25-year history of innovation is helping eye surgeons meet the moment.

Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

Expertise, innovation and insight are fueling the development of remote and AI-powered approaches to healthcare—potentially improving treatment decisions and evolving the way clinical trials are designed and managed.